Search Beyond News…

ADMA Biologics faces lead plaintiff deadline August 10 as investors urged to apply for securities class action

Executive summary: ClaimsFiler reminded investors with losses over $100,000 that they have until August 10, 2026 to file lead plaintiff applications in a securities class action lawsuit against ADMA Biologics, Inc. The lead plaintiff selection can shape litigation strategy, settlement talks, and ultimately affect ADMA's financial exposure and stock price.

Who is involved: ADMA Biologics, ClaimsFiler, investors holding ADMA shares with >$100,000 losses, and the court overseeing the class action.

Likely next: Investors will submit applications by the August 10 deadline; the court will then select a lead plaintiff, after which the case will proceed to discovery and potential settlement discussions.

ClaimsFiler has issued a reminder that investors who suffered losses exceeding $100,000 in ADMA Biologics must submit lead plaintiff applications by August 10, 2026 in an ongoing securities class action. The notice follows a previously filed lawsuit alleging securities fraud related to revenue inflation. Meeting the deadline is a prerequisite for being considered as the lead plaintiff, a role that can influence the direction and potential settlement of the litigation.

Timeline

Analysis — what this means

Likely next events

Sectors affected

Regulatory implications

Historical parallels

Key entities

Sources

Related cases

Browse the full archive →